TLRY Stock Overview
Tilray Brands, Inc. engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally.
Tilray Brands Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$3.00|
|52 Week High||US$13.95|
|52 Week Low||US$2.65|
|1 Month Change||-10.71%|
|3 Month Change||-14.29%|
|1 Year Change||-72.97%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-81.37%|
Recent News & Updates
Japan should permit medical cannabis, health ministry panel says
A health ministry panel in Japan recommended Thursday that the country allow the import, manufacture, and use of cannabis-derived medicines, applying the same approval process as pharmaceuticals. Announcing its findings in a report, the committee also said that Japan should do more to discourage the recreational use of cannabis. In Japan, cannabis passion is illegal but not its use, and the panel noted that only 1.4% of people in the country have ever tried marijuana, compared to 20-40% in the west. Citing cannabis-derived epilepsy drug Epidiolex, the committee noted that even if such treatments are approved in Japan, clinicians won’t be able to prescribe them due to limitations in the current Cannabis Control Act. Developed by Ireland-based Jazz Pharmaceuticals (JAZZ), Epidiolex has become the first CBD medication to undergo clinical trials in Japan for rare and severe forms of epilepsy. Meanwhile, on Wall Street, cannabis stocks opened higher on Thursday. Notable gainers included Columbia Care (OTCQX:CCHWF), Cresco Labs (OTCQX:CRLBF), TerrAscend (OTCQX:TRSSF), and Tilray (NASDAQ:TLRY)
Most Canadian cannabis LPs not following Aurora's decline after earnings disappointment
Although Aurora Cannabis (NASDAQ:ACB) reported fiscal 2022 Q4 earnings after Tuesday's closing that was seen as a disappointment to many leading to a share price decline, most other Canadian LPs are not following suit. Aurora is down 7% in early Wednesday afternoon trading. Cronos Group (NASDAQ:CRON) is higher by 1%, while Tilray Brands (NASDAQ:TLRY), Canopy Growth Corp. (NASDAQ:CGC), and Organigram Holdings (OGI) are all down by less than 1%. HEXO Corp. (HEXO) is down 3%. See why Seeking Alpha contributor Juxtaposed Ideas recently called Tilray (TLRY) a hold.
|TLRY||US Pharmaceuticals||US Market|
Return vs Industry: TLRY underperformed the US Pharmaceuticals industry which returned 4.4% over the past year.
Return vs Market: TLRY underperformed the US Market which returned -20% over the past year.
|TLRY Average Weekly Movement||13.2%|
|Pharmaceuticals Industry Average Movement||11.3%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: TLRY is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: TLRY's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Tilray Brands, Inc. engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company operates through four segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. It offers medical and adult-use cannabis products, including GMP-certified flowers, oils, vapes, edibles, and topicals; purchases and resells pharmaceutical and wellness products; and produces, markets, sells, and distributes beverage alcohol products, and hemp-based food and other wellness products.
Tilray Brands Fundamentals Summary
|TLRY fundamental statistics|
Is TLRY overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|TLRY income statement (TTM)|
|Cost of Revenue||US$511.56m|
Last Reported Earnings
May 31, 2022
Next Earnings Date
Oct 07, 2022
|Earnings per share (EPS)||-0.76|
|Net Profit Margin||-75.88%|
How did TLRY perform over the long term?See historical performance and comparison
Is TLRY undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for TLRY?
Other financial metrics that can be useful for relative valuation.
|What is TLRY's n/a Ratio?|
Price to Sales Ratio vs Peers
How does TLRY's PS Ratio compare to its peers?
|TLRY PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
HRMY Harmony Biosciences Holdings
SUPN Supernus Pharmaceuticals
CORT Corcept Therapeutics
AMPH Amphastar Pharmaceuticals
TLRY Tilray Brands
Price-To-Sales vs Peers: TLRY is good value based on its Price-To-Sales Ratio (3x) compared to the peer average (5.2x).
Price to Earnings Ratio vs Industry
How does TLRY's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?
Price-To-Sales vs Industry: TLRY is expensive based on its Price-To-Sales Ratio (3x) compared to the US Pharmaceuticals industry average (2.9x)
Price to Sales Ratio vs Fair Ratio
What is TLRY's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||3x|
|Fair PS Ratio||4.8x|
Price-To-Sales vs Fair Ratio: TLRY is good value based on its Price-To-Sales Ratio (3x) compared to the estimated Fair Price-To-Sales Ratio (4.8x).
Share Price vs Fair Value
What is the Fair Price of TLRY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate TLRY's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate TLRY's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
How is Tilray Brands forecast to perform in the next 1 to 3 years based on estimates from 17 analysts?
Future Growth Score1/6
Future Growth Score 1/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TLRY is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: TLRY is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: TLRY is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: TLRY's revenue (12.1% per year) is forecast to grow faster than the US market (7.6% per year).
High Growth Revenue: TLRY's revenue (12.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: TLRY is forecast to be unprofitable in 3 years.
Discover growth companies
How has Tilray Brands performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: TLRY is currently unprofitable.
Growing Profit Margin: TLRY is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: TLRY is unprofitable, and losses have increased over the past 5 years at a rate of 62.4% per year.
Accelerating Growth: Unable to compare TLRY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TLRY is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (5%).
Return on Equity
High ROE: TLRY has a negative Return on Equity (-9.77%), as it is currently unprofitable.
Discover strong past performing companies
How is Tilray Brands's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: TLRY's short term assets ($803.5M) exceed its short term liabilities ($280.3M).
Long Term Liabilities: TLRY's short term assets ($803.5M) exceed its long term liabilities ($728.0M).
Debt to Equity History and Analysis
Debt Level: TLRY's net debt to equity ratio (4.3%) is considered satisfactory.
Reducing Debt: TLRY's debt to equity ratio has increased from 12.2% to 13.6% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TLRY has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if TLRY has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
What is Tilray Brands's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|Tilray Brands Dividend Yield vs Market|
|Company (Tilray Brands)||n/a|
|Market Bottom 25% (US)||1.6%|
|Market Top 25% (US)||4.5%|
|Industry Average (Pharmaceuticals)||2.6%|
|Analyst forecast in 3 Years (Tilray Brands)||n/a|
Notable Dividend: Unable to evaluate TLRY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate TLRY's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if TLRY's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TLRY's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as TLRY has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Irwin Simon (64 yo)
Mr. Irwin David Simon is Lead Independent Director at Stagwell Inc. and has been its Director since April 25, 2013. Mr. Simon previously served as a member of Board of Directors of MDC Partners Inc. since...
CEO Compensation Analysis
|Irwin Simon's Compensation vs Tilray Brands Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|May 31 2022||n/a||n/a|
|Feb 28 2022||n/a||n/a|
|Nov 30 2021||n/a||n/a|
|Aug 31 2021||n/a||n/a|
|May 31 2021||US$14m||US$142k|
|Feb 28 2021||n/a||n/a|
|Nov 30 2020||n/a||n/a|
|Aug 31 2020||n/a||n/a|
|May 31 2020||US$13m||US$2m|
|Feb 29 2020||n/a||n/a|
|Nov 30 2019||n/a||n/a|
|Aug 31 2019||n/a||n/a|
|May 31 2019||US$7m||US$294k|
Compensation vs Market: Irwin's total compensation ($USD13.68M) is above average for companies of similar size in the US market ($USD5.50M).
Compensation vs Earnings: Irwin's compensation has increased whilst the company is unprofitable.
Experienced Management: TLRY's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Experienced Board: TLRY's board of directors are considered experienced (3.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: TLRY insiders have only sold shares in the past 3 months.
Recent Insider Transactions
|09 Aug 22||SellUS$46,800||David Hopkinson||Individual||12,000||US$3.90|
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 31.6%.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Tilray Brands, Inc.'s employee growth, exchange listings and data sources
- Name: Tilray Brands, Inc.
- Ticker: TLRY
- Exchange: NasdaqGS
- Founded: NaN
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$1.884b
- Shares outstanding: 628.07m
- Website: https://www.tilray.com
Number of Employees
- Tilray Brands, Inc.
- 265 Talbot Street West
- N8H 5L4
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|TLRY||TSX (The Toronto Stock Exchange)||Yes||Class 2 Common Shares||CA||CAD||Jun 2019|
|TLRY||NasdaqGS (Nasdaq Global Select)||Yes||Class 2 Common Shares||US||USD||Jun 2019|
|2HQ||DB (Deutsche Boerse AG)||Yes||Class 2 Common Shares||DE||EUR||Jun 2019|
|2HQ||SWX (SIX Swiss Exchange)||Yes||Class 2 Common Shares||CH||CHF||Jun 2019|
|2HQ||XTRA (XETRA Trading Platform)||Yes||Class 2 Common Shares||DE||EUR||Jun 2019|
|2HQ||BUL (Bulgaria Stock Exchange)||Yes||Class 2 Common Shares||BG||EUR||Jun 2019|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/10/04 00:00|
|End of Day Share Price||2022/10/04 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.